Review Article
Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Table 1
Basic characteristics of the eligible literature.
| | Author | Year | Registered name | Phase | No. | Arm 1 | Arm 2 | Endpoints |
| | Choueiri et al. [12] | 2021 | CheckMate 9ER | III | 651 | Nivolumab plus cabozantinib | Sunitinib | PFS, OS, AEs | | Motzer et al. [13] | 2020 | CheckMate 025 | III | 803 | Nivolumab | Everolimus | PFS, OS, AEs | | Albiges et al. [14] | 2020 | CheckMate 214 | III | 1096 | Nivolumab plus ipilimumab | Sunitinib | PFS, OS, AEs |
|
|
PFS, progression-free survival; OS, overall survival; AEs, adverse events.
|
